Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovateltide + Docetaxel in 2nd-line NSCLC
NCT01741155Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2013
- Primary completion
- Jul 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sovateltide in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc.. Started May 2013; status: terminated.
02
Drugs
sovateltide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01741155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01741155.